John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
TechTarget
TTGT
$281M
| $1.27M | ﹤0.01% |
38,407
-21,516
| -36% | -$708K |
|
|
ONTF
1752
DELISTED
ON24
ONTF
| $1.27M | ﹤0.01% |
177,559
+16,326
| +10% | +$119K |
|
|
RVNC
1753
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.27M | ﹤0.01% |
+257,397
| New | +$1.52M |
|
1754
GigaCloud Technology
GCT
$1.86B
| $1.27M | ﹤0.01% |
47,384
-294,625
| -86% | -$8.37M |
|
1755
Sportradar
SRAD
$3.82B
| $1.27M | ﹤0.01% |
+108,763
| New | +$1.15M |
|
|
ARIS
1756
Aris Mining
ARIS
$4.37B
| $1.26M | ﹤0.01% |
351,300
+272,600
| +346% | +$846K |
|
1757
RB Global
RBA
$15.7B
| $1.26M | ﹤0.01% |
16,575
-8,597
| -34% | -$601K |
|
1758
Pangaea Logistics
PANL
$549M
| $1.26M | ﹤0.01% |
180,865
+78,318
| +76% | +$641K |
|
1759
OR Royalties Inc
OR
$7.29B
| $1.26M | ﹤0.01% |
76,746
-30,591
| -28% | -$452K |
|
|
GPGI
1760
GPGI Inc
GPGI
$3.94B
| $1.26M | ﹤0.01% |
209,633
+33,886
| +19% | +$153K |
|
|
JVSA
1761
DELISTED
JV SPAC Acquisition Corp
JVSA
| $1.26M | ﹤0.01% |
+125,000
| New | +$1.26M |
|
1762
Hillman Solutions
HLMN
$1.58B
| $1.25M | ﹤0.01% |
117,926
-25,200
| -18% | -$235K |
|
|
HSII
1763
DELISTED
Heidrick & Struggles
HSII
| $1.25M | ﹤0.01% |
37,240
-29,096
| -44% | -$883K |
|
1764
iShares US Broker-Dealers & Securities Exchanges ETF
IAI
$1.43B
| $1.25M | ﹤0.01% |
+10,800
| New | +$1.17M |
|
1765
Rentokil
RTO
$12B
| $1.25M | ﹤0.01% |
+41,458
| New | +$1.15M |
|
|
NARI
1766
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $1.25M | ﹤0.01% |
26,030
-45,314
| -64% | -$2.42M |
|
|
DHC
1767
Diversified Healthcare Trust
DHC
$1.96B
| $1.25M | ﹤0.01% |
507,178
-502,435
| -50% | -$1.44M |
|
|
NAPA
1768
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $1.25M | ﹤0.01% |
133,971
-64,284
| -32% | -$589K |
|
1769
TPG
TPG
$8.82B
| $1.25M | ﹤0.01% |
27,903
-94,633
| -77% | -$4.05M |
|
1770
Avantis US Small Cap Value ETF
AVUV
$31.2B
| $1.25M | ﹤0.01% |
13,300
-15,300
| -53% | -$1.35M |
|
|
TRST
1771
Trustco Bank Corp NY
TRST
$969M
| $1.24M | ﹤0.01% |
44,206
+17,174
| +64% | +$486K |
|
1772
Karat Packaging
KRT
$985M
| $1.24M | ﹤0.01% |
43,500
-16,947
| -28% | -$447K |
|
1773
ARKO Corp
ARKO
$524M
| $1.24M | ﹤0.01% |
218,147
-27,101
| -11% | -$198K |
|
1774
Uranium Energy
UEC
$6.57B
| $1.24M | ﹤0.01% |
+184,142
| New | +$1.3M |
|
1775
Tredegar Corp
TG
$276M
| $1.24M | ﹤0.01% |
190,316
+14,700
| +8% | +$71.5K |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.